SpringLeaf jumps on $4M more for Series B round
Just a few months after coming out of stealth, SpringLeaf Therapeutics Inc. of Boston has bumped up its initial $15 million Series B fundraise to $19 million, the company reported in a release.
New investor on board is Excel Venture Management, which joined previous backers SR One, Flybridge Capital Partners and North Bridge Venture Partners in SpringLeaf’s first tranche of the Series B funding announced back in May. As part of the financing deal, Enrico Petrillo, managing director at Excel Venture Management, will join SpringLeaf’s board of directors as an observer. He joins Brian M. Gallagher Jr., partner at SR One – the venture capital arm of GlaxoSmithKline – on the board.